lifestyle.d-h.st

Author: Oruka Therapeutics, Inc.

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

April 27, 2026
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

April 27, 2026
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

April 26, 2026
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 12, 2026
Oruka Therapeutics to Participate in Multiple Upcoming Conferences

February 12, 2026